Leonardo Gil-Santana, MD

Clinical Oncologist 🇧🇷 → 🇨🇦
Early-phase trials & thoracic tumors |
Biomarkers • targeted therapy
Future DDP1 Fellow @pmcancercentre |
#PegaLeão 🦁 ⚽️

[Leonardo Gil-Santana, MD @leogilsan]

@ether_fi 1 Portugal
2 England
3 Ghana
4 Colombia
https://t.co/z4mTLxzlJh
#EtherFiWC26

[Leonardo Gil-Santana, MD @leogilsan]

@ether_fi 1 France
2 Norway
3 Argentina
4 Austria
https://t.co/g3lxpKGFTD
#EtherFiWC26

[Leonardo Gil-Santana, MD @leogilsan]

@ether_fi 1. Brazil
2. Scotland
3. Turkey

https://t.co/g3lxpKGFTD
#EtherFiWC26

[Chul Kim @chulkimMD]

Our paper on integrated molecular profiling of thymic epithelial tumors (TETs) is now out in @JCOPO_ASCO!

We analyzed 138 TET samples using whole-exome + whole-transcriptome sequencing to map the genomic landscape of thymomas and thymic carcinoma (TC).

https://t.co/NhXpL9Mny8

[Leonardo Gil-Santana, MD @leogilsan]

@chulkimMD @JCOPO_ASCO Congratulations to you and team! Amazing work 👏👏👏👏

[GBOT Alerta @GBOT_Alerta]

🚨 GBOT ALERTA – CROWN 7 anos

Lorlatinibe mantém benefício sem precedentes em 1L para CPCNP ALK+ avançado.

📌 PFS mediana ainda não alcançada após ~7 anos
📌 PFS em 7 anos: 55% vs 3% com crizotinibe
📌 Redução de 81% no risco de progressão ou morte (HR 0,19)

🧠 Controle intracraniano sem precedentes:
• Redução de 94% no risco de progressão cerebral (HR 0,06)
• Nenhuma nova progressão intracraniana após 30 meses
• PFS intracraniana em 7 anos: 92%
• Em pacientes sem metástases cerebrais ao diagnóstico, 96% permaneceram livres de novas lesões em 7 anos

✅ Sem alterações nos dados de segurança
✅ Redução de dose não compromete eficácia

🎯 Mais da metade dos pacientes permanece viva e sem progressão após 7 anos — a mais longa PFS já relatada para uma terapia-alvo isolada em tumores sólidos metastáticos.

#NSCLC #ALK #Lorlatinib #CROWN #OncologiaTorácica
@IASLC @SBOC_Oncologia @ASCOPost

[Vladmir C. Cordeiro de Lima, MD, PhD @ClaudioVladmir]

📣We had two abstracts selected to be presented at ASCO 2026! A survey about liquid biopsy use in LATAM (Abst 9029) and an analysis of the impact of post-progression access to active therapies on OS in RCT (Abst 1500 - oral session).
👏Congratulations to Dr. Leonardo Santana e Dr. João Apolinário.
🤩Happy and proud!
A shout out also to abstratcs in collaboration with Dr. Elizabeth Santana on hereditary breast cancer, male brrast cancer and use ok CDKi!

[Chul Kim @chulkimMD]

#LORIN (neoadjuvant #lorlatinib) in ALK+ NSCLC: residual disease shows DTPC heterogeneity with persistent TROP2/proliferative signaling. In non-MPR, LAPTM4B/MDM2-high, FOLR1/FRα, and MET DTPCs expand - supporting rational combination strategies to target resistant clones. #ASCO26

[Daniel V. Araujo @DVAraujoMD]

@NEJM dropping the full embargoed LBA at 6am before the #ASCO26 presentation is like texting someone the movie ending while they're still parking the car. At least let us pretend we don't know. 🍿

[Chul Kim @chulkimMD]

This will be remembered as one of the most important clinical trials in the history of oncology.

#ASCO26

[Leonardo Gil-Santana, MD @leogilsan]

Amazing to finally meet @chulkimMD in person. Thank you for your mentorship and guidance. Looking forward to advancing thymoma projects. @IASLC

[Chul Kim @chulkimMD]

Seven-year follow-up of CROWN confirms the durability of first-line #lorlatinib in ALK+ NSCLC: 55% remain progression-free at 7 years, median PFS unreached, and intracranial control is unprecedented (HR for IC progression 0.06). A new benchmark in targeted therapy. #ASCO26

[Balazs Halmos @BalazsHalmosMD]

Sun-vozertinib rose over the frontline horizon today showing improved PFS over doublet chenotherapy for pts w advanced EGFR exon 20insertion mutation positive pts and w an oral option could be a fair 1st line option along w PAPILLON

But noting a somewhat mediocre PFS of slightly >10m, notable adverse event profile (40%+ dose reductions) and unclear CNS activity, the therapeutic window for exon20 ins+ pts remains narrow- the window for better drugs remains wide
#ASCO26
#lcsm

[d.planchard @dplanchard]

Sunvozertinib (WU-KONG28 trial): a new major player on front line to replace chemoT - Amivantamab: very likely and while awaiting the next ones, including firmonertinib for EGFR Ex20ins pts. World of EGFR definitely never stops its scientific revolution and progress…@NEJM #EGFR

[Sujith @sujithonco]

Inviting to join the Global Oncology community, get access to Education resources and online classes.

Join the special session of Global Oncology
https://t.co/vglwCu8jFw

@nnadiagee
@JCOGO_ASCO @ASCO @venkymd @Amolpatel_dr @leogilsan @LauBernalOnc @AmalAljuhani27 @GevTamamyan

[Aakash Desai, MD, MPH, FASCO @ADesaiMD]

ICYMI, @ASCO abstracts release next week! Here's my top 10 lists for:
👉 Lung Cancer Abstracts to watch #lcsm
👉 Devp. therapeutics Abstracts to watch
👉 #AI in oncology Abstracts to watch
and ofcourse, the #plenaries
2 weeks to go for #ASCO26! @OncoAlert @oncodaily

[GBOT Alerta @GBOT_Alerta]

🚨 GBOT ALERTA – Estadiamento mediastinal no CPCNP

Diretriz do Grupo Brasileiro de Oncologia Torácica (GBOT):

📌 TC e PET-CT têm acurácia limitada para N2/N3
• sROC: 0,73 e 0,87
⚠️ PET-CT pode gerar falso-positivos em áreas endêmicas para granulomatoses (ex: TB)

✅ EBUS + EUS = maior acurácia diagnóstica
• sROC: 0,99
• Performance comparável à mediastinoscopia

🧠 Pontos-chave:
• Imagem isolada NÃO basta
• Confirmação tecidual é essencial
• EBUS/EUS deve ser primeira linha
• Mediastinoscopia fica reservada para casos selecionados

🎯 Estadiamento preciso evita cirurgias desnecessárias e acelera o tratamento.

#NSCLC #EBUS #EUS #PETCT #OncologiaTorácica
#GBOTjovem
@SBOC_Oncologia @IASLC

https://t.co/MgMAdfokkA

[Daniel Castellano @cdanicas]

🎯🔥⚽️the most funky, friendly, fashioned social event is coming again!! 💪💪 @ASCO @ASCOPres
🚀 The World #ASCO26 football Cup! @DrChoueiri @FAndreMD
📆 Saturday May 30th (6.00-10.00PM)
Registration is open
Contact: [email protected]
🙌🙌Brasil, Argentina, Colombia,Peru and USA are confirmed🏃‍♂️🏃‍♂️
The latest versions were a lot of fun. 😎 Don't miss it and sign up!🔥
With a rock stars @DrChoueiri !!
@OncoAlert @aaoncoclinica @SoaresAndrey @myESMO @raymanneh @GuardConsortium @DrFelixGuerrero

[Leonardo Gil-Santana, MD @leogilsan]

@chulkimMD 👏👏👏

[Chul Kim @chulkimMD]

May is Thymic Malignancy Awareness Month!

Join us for a FREE webinar series covering the latest in thymic epithelial tumors.

Register: https://t.co/tGQue7ojq7

📋 May 20 — Clinical Guidelines Updates
🏥 May 20 — Multidisciplinary Care: Surgery to QoL
🧬 May 22 — Clinical Trials & Emerging Therapies
🔬 May 28 — Challenges in Thymic Tumor Pathology
🌍 Jun 9 — Treatment Access Worldwide

@Itmig_society